Xvivo Perfusion ABXVIPF -1.32%91 Shiller PE Ratio is 263.65 as of Jul. 07, 2026, which is 63% below its 10-year median of 705.13. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $41.71 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 312 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks worse than 96.79% on this metric.
The historical rank and industry rank for Xvivo Perfusion AB's Shiller PE Ratio or its related term are showing as below:
XVIPF'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 186.48 Med: 705.13 Max: 1814.29
Current: 261.09
During the past years, Xvivo Perfusion AB's highest Shiller PE Ratio was 1814.29. The lowest was 186.48. And the median was 705.13.
XVIPF's Shiller PE Ratio is ranked worse than 96.79% of 312
companies
in the Medical Devices & Instruments industry
Industry Median: 24.315
vs XVIPF: 261.09
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Xvivo Perfusion AB's adjusted earnings per share data for the three months ended in Mar. 2026 was $0.123. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.11 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Xvivo Perfusion AB (OTCPK:XVIPF) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Xvivo Perfusion AB Shiller PE Ratio Related Terms
Xvivo Perfusion AB Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XVIPF vs ABT, SYK, MDT: Shiller PE Ratio Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Shiller PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Xvivo Perfusion AB (XVIPF) has a Shiller PE Ratio of 263.65 as of Jul. 07, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Xvivo Perfusion AB and its competitors. This is 63% below median its historical median of 705.13. Over the past decade, Xvivo Perfusion AB's Shiller PE Ratio has ranged from 186.48 to 1,814.29. According to the industry distribution chart, Xvivo Perfusion AB ranks #302 out of 312 companies in the Medical Devices & Instruments industry, placing it in the top 96.8%.
Is Xvivo Perfusion AB's Shiller PE Ratio too high?
Xvivo Perfusion AB's current Shiller PE Ratio of 263.65 is 63% below median its 10-year median of 705.13. Over the past 10 years, this metric has ranged from a low of 186.48 to a high of 1,814.29. The Medical Devices & Instruments industry median Shiller PE Ratio is 24.32. Xvivo Perfusion AB's value of 263.65 is 984.3% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #302 out of 312 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Shiller PE Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #302 out of 312 companies for Shiller PE Ratio. This places Xvivo Perfusion AB in the lower half of its industry. The industry median Shiller PE Ratio is 24.32. Xvivo Perfusion AB's value of 263.65 is 984.3% above this benchmark. Historically, Xvivo Perfusion AB's own Shiller PE Ratio has ranged from 186.48 to 1,814.29 over the past decade. While the company's 10-year median is 705.13 vs. the industry median of 24.32, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Medical Devices & Instruments company?
The median Shiller PE Ratio among Medical Devices & Instruments companies is 24.32, based on 312 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Shiller PE Ratio of 263.65 is 984.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Shiller PE Ratio is 24.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Shiller PE Ratio is 263.65, which is 63% below median its own 10-year median of 705.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $41.71, compared to a current price of $29.00 — trading 30.5% below its estimated fair value. The current Shiller PE Ratio is 263.65, which is 63% below median its 10-year median of 705.13 and 984.3% above the Medical Devices & Instruments industry median of 24.32. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Shiller PE Ratio is 263.65 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 30.5% below its estimated GF Value™ of $41.71.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Shiller PE Ratio: 263.65 (63% below median its 10-year median of 705.13)
GF Value™: $41.71 vs. price of $29.00 (30.5% below fair value)
Industry Position: 984.3% above the Medical Devices & Instruments median (#302 of 312)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
